Bispecific Platform
Bispecific Platform
Proprietary Heterodimeric Fc and Cognate HC-LC Pairing Technology
Proprietary Heterodimeric Fc
and HC-LC Pairing Technology
Advantages of Bispecific Monoclonal Antibodies
Advantages of Bispecific Monoclonal Antibodies
Bispecific monoclonal antibodies combine two distinct antigen-binding specificities within a single antibody molecule, enabling simultaneous targeting of different molecules or biological pathways. This approach offers opportunities for enhanced therapeutic activity and novel mechanisms of action. Sound Biologics' proprietary heterodimeric Fc technology facilitates the development of stable, IgG-like bispecific antibodies while supporting cognate antibody assembly and robust production.
Bispecific monoclonal antibodies combine two distinct antigen-binding specificities within a single antibody molecule, enabling simultaneous targeting of different molecules or biological pathways. This approach offers opportunities for enhanced therapeutic activity and novel mechanisms of action. Sound Biologics' proprietary heterodimeric Fc technology facilitates the development of stable, IgG-like bispecific antibodies while supporting cognate antibody assembly and robust production.
Engineering Bispecific Monoclonal Antibodies
Engineering Bispecific Monoclonal Antibodies
Sound Biologics has developed proprietary Fc engineering technology to control the formation of stable heterodimeric bispecific antibodies. Through engineering the interface residues in the CH3 domains, the platform favors pairing between two different heavy chains while minimizing unwanted homodimer formation. Additional engineering of heavy-chain/light-chain interfaces assures correct chain pairing, enabling robust assembly of full-length bispecific antibodies with two distinct binding specificities.
Sound Biologics has developed proprietary Fc engineering technology to control the formation of stable heterodimeric bispecific antibodies. Through engineering the interface residues in the CH3 domains, the platform favors pairing between two different heavy chains while minimizing unwanted homodimer formation. Additional engineering of heavy-chain/light-chain interfaces assures correct chain pairing, enabling robust assembly of full-length bispecific antibodies with two distinct binding specificities.
Bispecific Platform — Intellectual Property
Bispecific Platform — Intellectual Property
A patent covering Sound Biologics' proprietary heterodimeric Fc engineering technology has been issued in the United States, with corresponding applications pending in China and the European Union. U.S. Patent No. 12,441,816 B2 ➤, titled Heterodimeric Fc for Making Fusion Proteins and Bispecific Antibodies, is available for reference.
A patent covering Sound Biologics' proprietary heterodimeric Fc engineering technology has been issued in the United States, with corresponding applications pending in China and the European Union. U.S. Patent No. 12,441,816 B2 ➤, titled Heterodimeric Fc for Making Fusion Proteins and Bispecific Antibodies, is available for reference.
➤
➤
Back to Our Science
Back to Our Science
